TOVX (Theriva Biologics) קפיטליזציה חשבונאית

Theriva Biologics, Inc. (TOVX) develops oncolytic viruses to combat gastrointestinal tumors, leveraging long-term patents and government procurement. Business success is based on patient survival rates and partner support, with the current metric standing at 0.01. A stable staff of leading oncologists and manufacturing experts ensures R&D continuity. The following charts illustrate the price evolution of the company's shares.

Book value capitalization determines the net asset value minus all liabilities, capturing the actual volume of equity as a guarantee for investment protection. The current book value of capital at 0.01 reflects the financial stability of Theriva Biologics, Inc., confirming the company's ability to maintain costly temperature control infrastructure and biologics logistics for oncology research.